Tag: Pulmonary Embolism

BTG plc Release: OPTALYSE PE Long Term Results Reinforce Safety and Efficacy of Shorter, Lower Dose EKOS Therapy For Pulmonary Embolism

Peripheral/Endo by 0 comments

BOTHELL, Wash.–(BUSINESS WIRE)– BTG plc (LSE: BTG), the global healthcare company, today highlighted OPTALYSE PE one year trial results, presented at the International Society on Endovascular Therapy in Florida. The findings confirm that bilateral pulmonary embolism patients treated in as little as 2 hours with a total tissue plasminogen activator (tPA) dose […]

Continue Reading →

Centers Commence Enrollment in KNOCOUT PE Study to Measure the Impact of Shorter, Even Safer EKOS® Therapy Protocols for Pulmonary Embolism

Peripheral/Endo by 0 comments

BOTHELL, Wash.–(BUSINESS WIRE)–BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how hospitals and patients are benefitting from a new standard of care in the treatment of Pulmonary Embolism utilizing EKOS® therapy with faster, and even […]

Continue Reading →

Inari Medical Announces Completion of Patient Enrollment in the FLARE Study for the Treatment of Pulmonary Embolism

Peripheral/Endo Radiology by 0 comments

IRVINE, Calif., Oct. 24, 2017 /PRNewswire/ — Inari Medical, Inc., a privately held venture backed medical device company dedicated to the development of innovative catheter-based technologies for the treatment of venous thromboembolism (“VTE”), announced today it has completed enrollment of its Investigational Device Exemption (“IDE”) study. The FlowTriever Pulmonary Embolectomy Clinical Study (“FLARE”) […]

Continue Reading →